BNT329 for Advanced solid tumors that express the tumor marker CA19-9
BioNTech SE(BNTX)
Reviewed by Blane Jackson, DDS, MBA. Educational analysis only. Read the editorial policy and disclosures.
NCT07186842 on ClinicalTrials.gov →Study type
interventional
Design
First-in-human, open-label, mu…
Target enrollment
245
Est. completion
2030-05
Investor scorecard
Probability of success
low
Timeline to catalyst
Initial safety and efficacy data from dose escalation may be available in 2026-2027. Expansion cohort data (Part D) could be available around 2028-2029. The trial is expected to complete in 2030.
Potential stock impact
SignificantFirst-in-human oncology trials have a low probability of success, historically around 5-10% for eventual approval. The drug is targeting a novel antigen (CA19-9) with an ADC, which adds complexity. There is also competition from other ADCs. However, BioNTech has a strong track record in drug development, and the trial design is thorough. The probability is low but not negligible.
What is being tested?
BNT329 is an investigational drug being developed by BioNTech. It is a type of targeted therapy called an antibody-drug conjugate (ADC). Think of it as a guided missile: one part (the antibody) specifically recognizes and binds to a protein called CA19-9, which is found on the surface of many solid tumor cells. The other part (the drug payload) is a toxic chemical that kills the cancer cell once delivered. This trial is testing whether BNT329 is safe and shows promise in shrinking tumors in patients with advanced solid cancers that express CA19-9. CA19-9 is a marker often elevated in pancreatic, colorectal, and other gastrointestinal cancers.
How does the trial work?
This is a first-in-human trial, meaning BNT329 has never been given to people before. It is an open-label study, so both doctors and patients know they are receiving the drug. The trial has multiple parts: Part A and B are dose escalation phases, where small groups of patients receive increasing doses to find the highest dose that is safe (maximum tolerated dose). Part D is an expansion phase, where more patients receive the recommended dose to further evaluate safety and see how well it works. The trial is randomized and sequential, meaning patients are assigned to different dose levels in a specific order. Participants will receive BNT329 as an intravenous infusion, likely every few weeks. They will be monitored closely for side effects, and their tumors will be measured periodically to see if they shrink.
What does success look like?
Success in early-phase trials is primarily about safety and signs of efficacy. The primary endpoints include the occurrence of dose-limiting toxicities (side effects that prevent increasing the dose) and other adverse events. If too many patients experience severe side effects, the trial may be halted. For efficacy, the objective response rate (ORR) is key: the percentage of patients whose tumors shrink by a certain amount (partial response) or disappear (complete response). In similar trials for advanced solid tumors, an ORR of 20-30% is often considered promising, but it depends on the cancer type. The trial will also look at how the drug behaves in the body (pharmacokinetics), such as how long it stays in the blood. Ultimately, success means the drug is tolerable and shows enough anti-tumor activity to warrant further testing.
What it means for investors
For investors, this trial is a high-risk, high-reward opportunity. BioNTech is a major biotech known for its COVID-19 vaccine, but this is a different area: oncology. The trial is early-stage (Phase I/IIa), so the probability of success is low, but the potential market is huge if it works. CA19-9 is expressed in many hard-to-treat cancers, including pancreatic cancer, which has few effective treatments. If BNT329 shows strong efficacy and a manageable safety profile, it could become a significant revenue driver. However, early-phase data can be misleading, and many drugs fail in later stages. Investors should watch for safety signals and any hints of tumor shrinkage. Positive data could boost BioNTech's stock, while negative data could cause a decline. The timeline is long (completion expected in 2030), so this is a long-term bet.
Trial endpoints
Primary endpoints
Secondary endpoints
Competitive landscape
The addressable market for BNT329 includes patients with advanced solid tumors expressing CA19-9, which encompasses a significant portion of pancreatic, colorectal, gastric, and biliary tract cancers. Pancreatic cancer alone has a 5-year survival rate of about 10%, and there is a high unmet need. The global cancer immunotherapy market is expected to exceed $100 billion by 2030. If BNT329 proves effective, it could capture a share of this market, especially if it shows activity in pancreatic cancer, where current options are limited. However, competition is fierce, with many ADCs in development. The success of BNT329 will depend on its efficacy and safety relative to existing and emerging therapies.
| Drug | Sponsor | Phase | Differentiation |
|---|---|---|---|
| Enhertu (trastuzumab deruxtecan) | Daiichi Sankyo/AstraZeneca | Phase 1 | Targets HER2, not CA19-9, but is an ADC with a similar mechanism. Approved for several HER2-positive cancers. |
| Trodelvy (sacituzumab govitecan) | Gilead Sciences | Phase 1 | Targets Trop-2, another tumor marker, and is approved for triple-negative breast cancer and other solid tumors. |
| ADC for CA19-9 (e.g., MVT-5873) | MabVax Therapeutics (now part of BioAtla?) | Phase 1 | Another CA19-9-targeting antibody, but not an ADC; it is a naked antibody. May have different efficacy and safety profile. |
Historical context
Prior trial results
This is a first-in-human trial, so there are no prior clinical results for BNT329. However, preclinical studies in animal models likely showed anti-tumor activity and acceptable safety, which justified moving to humans.
Regulatory history
No regulatory designations (e.g., Fast Track, Breakthrough Therapy) have been publicly announced for BNT329. The trial is currently recruiting, and no regulatory submissions have been made.
Similar drug precedents
ADCs have had mixed success in oncology. Some, like Enhertu and Trodelvy, have been highly successful and gained approvals. Others have failed due to toxicity or lack of efficacy. The key is finding the right target and having a stable linker and potent payload. CA19-9 is a challenging target because it is a carbohydrate antigen, and targeting it with an ADC is relatively novel. Historically, antibodies targeting CA19-9 have been explored but not approved. The precedent suggests that targeting CA19-9 is feasible, but the ADC approach may offer better efficacy if the payload is potent enough.